We demonstrate that these patient-derived dopaminergic cells recapitulate the main biochemical abnormalities seen in PD postmortem brain and that through the use of a small-molecule chaperone, GCase activity can be increased and α-synuclein levels reduced. The gene discussed is SNCA; the disease is Parkinson disease.